Akèy › Karsinòm selil skuamèz tèt ak kou › Kalifòni › Sacramento
Etid klinik pou Karsinòm selil skuamèz tèt ak kou nan Sacramento, CA
8 etid pou Karsinòm selil skuamèz tèt ak kou ap chèche patisipan nan sit nan ak bò kote Sacramento (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Ap rekriteFaz 2/3
- Site#0144, Sacramento
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Ap rekriteFaz 3
- University Of California - Davis, Sacramento
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Ap rekriteFaz 2
- Mercy Cancer Center - Sacramento, Sacramento
- Woodland Memorial Hospital, Woodland · 16 mi lwen
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- University of California Davis Comprehensive Cancer Center, Sacramento
- University of California, Davis Medical Center, Sacramento
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- University of California, Davis Comprehensive Cancer Center, Sacramento
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 1
- University of California Davis Comprehensive Cancer Center, Sacramento
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- University of California Davis Comprehensive Cancer Center, Sacramento
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Ap rekriteFaz 1
- University of California, Davis Comprehensive Cancer Center, Sacramento
Etid Karsinòm selil skuamèz tèt ak kou nan lòt vil
- Houston, TX47 etid
- Los Angeles, CA42 etid
- Boston, MA40 etid
- Nashville, TN39 etid
- New York City, NY39 etid
- St. Louis, MO28 etid
- Arlington, VA26 etid
- Philadelphia, PA26 etid
- Chicago, IL26 etid
- Atlanta, GA24 etid
- San Antonio, TX22 etid
- Pittsburgh, PA22 etid
Lòt etid nan Sacramento
- Kansè Poumon ki pa ti selil29 etid
- Kansè poumon22 etid
- Kansè nan tete20 etid
- Kansè pwostat19 etid
- Kansè Metastatik16 etid
- Leksemi mieloïd egi12 etid
- Ensifizyans kadyak12 etid
- Kansè pankreyas12 etid
- Kansè (tout kalite)11 etid
- Kansè kolon11 etid
- Kansè vejik10 etid
- Kansè kolorektal10 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.